Subtype
Thyroid Gland Anaplastic Carcinoma
CI-CAN-00004121ATCExplore in graph →
22 active trials2 approved drugs5 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004121ATCExplore in graph →
Variants & evidence
22 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|
| BRAF V6001 | |||||||
| Dabrafenib/Trametinib Regimen | Predictive | C | Supports Sensitivity Response | 1 | submitted | EID12797A 63-year-old female patient presented with BRAF V600E-mutant anaplastic thyroid cancer (ATC). Following three surgical resections and a new chemotherapy regimen the patient was diagnosed with lung me… (full text at CIViC) PMID 37900238 · Lee et al., 2023 · Open in CIViC | civic |
| BRAF V600E18 | |||||||
| (oncogenic) | Oncogenic | B | Supports Oncogenicity | 3 | submitted | EID13014A systematic review and meta-analysis of 34 studies comprising 978 patients with anaplastic thyroid carcinoma (ATC) reported a pooled prevalence of BRAF V600E of 33% (95% CI, 26%–40%). When cases with… (full text at CIViC) PMID 39086414 · Behnagh et al., 2024 · Open in CIViC | civic |
| 〃 | Oncogenic | B | Supports Oncogenicity | 3 | submitted | EID13015Targeted next-generation sequencing of 11 anaplastic thyroid carcinomas (ATCs) with matched normal tissue identified BRAF V600E in 10 of 11 tumors (91%), making BRAF the most frequently mutated gene i… (full text at CIViC) PMID 26980298 · Jeon et al., 2016 · Open in CIViC | civic |
| 〃 | Oncogenic | B | Supports Oncogenicity | 3 | rejected | EID13016Comprehensive genomic profiling of 68 anaplastic thyroid carcinomas (ATCs) identified BRAF alterations in 10.3% of tumors. BRAF mutations were more common in ATCs with a concurrent or prior papillary … | |
| CCND1 Overexpression1 | |||||||
| Ribociclib | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID7790Study observed the effects of ribociclib (LEE011) on anaplastic thyroid cancer (ATC) and papillary thyroid cancer (PTC) cells. qRT-PCR found Cyclin D1 mRNA to have significantly higher expression in A… (full text at CIViC) PMID 29306020 · Lee et al., 2018 · Open in CIViC | civic |
| MTOR F2108L1 | |||||||
| Everolimus | Predictive | C | Supports Resistance | 5 | accepted | EID1110After an 18-month sustained response to everolimus (in a patient with metastatic anaplastic thyroid carcinoma whose pretreatment tumor harbored a TSC2 Q1178* inactivating mutation, see EID1108), the r… (full text at CIViC) PMID 25295501 · Wagle et al., 2014 · Open in CIViC | civic |
| ALK Fusion1 | |||||||
| Crizotinib | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID5954A patient with anaplastic thyroid carcinoma harboring ALK rearrangement received crizotinib after chemotherapy for pulmonary recurrence. Crizotinib showed confirmed response of more than 90% by tumor … (full text at CIViC) PMID 24687827 · Godbert et al., 2015 · Open in CIViC | civic |
Data updated 22 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
PMID 40674659 · Trivedi et al., 2025 · Open in CIViC
| civic |
| 〃 | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID13011In BRAF V600E-positive murine anaplastic thyroid carcinoma (ATC) cell lines (TBP-3743, TBPt-3403, and TBPt-3610R), treatment with the BRAF inhibitor PLX4720 decreased ERK phosphorylation and significa… (full text at CIViC) PMID 24994118 · Vanden Borre et al., 2014 · Open in CIViC | civic |
| 〃 | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID13012In an orthotopic mouse model generated using BRAF V600E-positive 8505c anaplastic thyroid carcinoma cells, treatment with the selective BRAF V600E inhibitor PLX4720 decreased phospho-ERK1/2 expression… (full text at CIViC) PMID 22202162 · Nehs et al., 2012 · Open in CIViC | civic |
| Dabrafenib + TrametinibCombination | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID6975Interim analysis of a basket trial evaluating the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in previously treated V600E-mutated patients showed 11/16 patients with anap… (full text at CIViC) PMID 29072975 · Subbiah et al., 2018 · Open in CIViC | civic |
| 〃 | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID12960In this systematic review and meta-analysis, the authors evaluated the predictive relevance of the BRAF V600E variant in patients with anaplastic thyroid carcinoma (ATC) treated with MAPK pathway-targ… (full text at CIViC) PMID 38709445 · Priantti et al., 2024 · Open in CIViC | civic |
| 〃 | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID12957In this retrospective, single-center, real-world study conducted between May 2018 and April 2022, 27 patients with anaplastic thyroid carcinoma (ATC) were stratified into three groups: patients with B… (full text at CIViC) PMID 36651156 · da Silva et al., 2023 · Open in CIViC | civic |
| 〃 | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID12959This multi-institutional retrospective study analyzed 44 patients with anaplastic thyroid carcinoma (ATC) treated across three hospitals in Taiwan. BRAF mutation testing was performed in 24 patients (… (full text at CIViC) PMID 36504909 · Chang et al., 2022 · Open in CIViC | civic |
| 〃 | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID13282In a single-center retrospective study of 6 patients with BRAF V600E-positive anaplastic thyroid carcinoma treated with dabrafenib plus trametinib, 4/6 patients (67%; 95% CI 24–94%) achieved an object… (full text at CIViC) PMID 40844731 · Ando et al., 2025 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID12956A 47-year-old woman with advanced metastatic anaplastic thyroid carcinoma (ATC) harboring a BRAF V600E mutation, identified by comprehensive genomic profiling of a resected lung metastasis, received c… (full text at CIViC) PMID 27697975 · Agarwal et al., 2016 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID12958This single-patient case report describes a 63-year-old woman diagnosed with BRAF V600E-mutated anaplastic thyroid carcinoma (ATC). Following multiple surgical resections, the patient developed recurr… (full text at CIViC) PMID 37900238 · Lee et al., 2023 · Open in CIViC | civic |
| Dabrafenib/Trametinib Regimen | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID10785An updated analysis of the phase 2 ROAR basket trial evaluating combination dabrafenib and trametinib in 36 BRAF V600E mutated anaplastic thyroid carcinoma patients (16 patients previously described i… (full text at CIViC) PMID 35026411 · Subbiah et al., 2022 · Open in CIViC | civic |
| Dabrafenib + Pembrolizumab + TrametinibCombination | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID13283In a retrospective single-center cohort of patients with BRAF V600E-mutated anaplastic thyroid carcinoma, 30 patients treated with upfront dabrafenib, trametinib, and pembrolizumab had a significantly… (full text at CIViC) PMID 38226606 · Hamidi et al., 2024 · Open in CIViC | civic |
| Vemurafenib | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID6045In a phase 2 “basket” study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete res… (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC | civic |
| 〃 | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID3744In an 80 year old female anaplastic thyroid cancer patient harboring BRAF V600E and TP53 E180K co-mutations, BRAF V600E was associated with response to vemurafenib treatment. Prior to identification o… (full text at CIViC) PMID 27532222 · Prager et al., 2016 · Open in CIViC | civic |
| Pertuzumab + VemurafenibCombination | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID5961The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC | civic |
| Radiation Therapy + VemurafenibCombination | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID3743A 51 year old male anaplastic thyroid cancer patient harboring BRAF V600E experienced rapid improvement in response to vemurafenib. The patient was initially treated with paclitaxel and carboplatin bu… (full text at CIViC) PMID 23406047 · Rosove et al., 2013 · Open in CIViC | civic |